American Journal of Cardiology最新文献

{"title":"Outcomes and Predictors of Different Flow-Gradient Patterns of Aortic Stenosis After Transcatheter Aortic Valve Replacement","authors":"Besir Besir MD ,&nbsp;Shivabalan Kathavarayan Ramu MD ,&nbsp;Maryam Muhammad Ali Majeed-Saidan MD ,&nbsp;Judah Rajendran MD ,&nbsp;Odette Iskandar MD ,&nbsp;Grant Reed MD ,&nbsp;Rishi Puri MD ,&nbsp;James Yun MD ,&nbsp;Serge Harb MD ,&nbsp;Rhonda Miyasaka MD ,&nbsp;Amar Krishnaswamy MD ,&nbsp;Zoran Popovic MD ,&nbsp;Samir R. Kapadia MD","doi":"10.1016/j.amjcard.2025.01.019","DOIUrl":"10.1016/j.amjcard.2025.01.019","url":null,"abstract":"<div><div>This study sought to explore the clinical factors associated with classical low-flow low-gradient (C-LFLG) and normal-flow low-gradient (NFLG) aortic stenosis (AS) compared with high-gradient (HG) AS. We also compared clinical and echocardiographic outcomes after transcatheter aortic valve replacement (TAVR) across flow-gradient patterns. Patients with C-LFLG AS have a higher mortality rate after TAVR than those with HG AS. However, what leads to C-LFLG AS and the predictors of mortality in this population remain unclear. In this retrospective, single-center study involving 1,415 patients with severe AS, patients were classified as having (1) HG AS (aortic valve mean gradient [MG] &gt;40 mm Hg), (2) C-LFLG AS (MG &lt;40 mm Hg, stroke volume index &lt;35 ml/m², left ventricular ejection fraction &lt;50%), and (3) NFLG AS (MG &lt;40 mm Hg, stroke volume index ≥35 ml/m², left ventricular ejection fraction ≥50%). Logistic regression was used for predictors of C-LFLG AS. Cox regression was used for predictors of mortality in the C-LFLG AS population. Male gender, multiple co-morbidities, and moderate to severe mitral and tricuspid regurgitation correlated with the C-LFLG AS group. Patients with C-LFLG AS had a higher mortality risk compared with patients with HG AS at 2 years after TAVR. Patients with NFLG AS had similar mortality at 1 year, but higher mortality at 2 years after TAVR compared with patients with HG AS. End-stage renal disease, atrial fibrillation, and other co-morbidities were predictors of 2-year mortality in patients with C-LFLG AS. In conclusion, the mortality rate after TAVR was higher among patients with C-LFLG AS than those with HG AS. Male gender and multiple co-morbidities were predictors of C-LFLG AS. Multiple co-morbidities were predictors of mortality among those patients.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"242 ","pages":"Pages 42-52"},"PeriodicalIF":2.3,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143035913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Vessel Responses Following Combined Sirolimus-Eluting and Endothelial Progenitor Cell Stent and Ultra-Thin Sirolimus-Eluting Stent Implantation by Serial Optical Coherence Tomography and Coronary Angioscopy: A Multicenter Observational Study","authors":"Daisuke Nakamura MD ,&nbsp;Isamu Mizote MD, PhD ,&nbsp;Takayuki Ishihara MD ,&nbsp;Yutaka Matsuhiro MD ,&nbsp;Shota Okuno MD, PhD ,&nbsp;Tatsuya Shiraki MD ,&nbsp;Takuya Tsujimura MD ,&nbsp;Naotaka Okamoto MD ,&nbsp;Naoki Itaya MD ,&nbsp;Takaharu Nakayoshi MD ,&nbsp;Atsushi Kikuchi MD ,&nbsp;Tsutomu Kawai MD ,&nbsp;Yuhei Nojima MD, PhD ,&nbsp;Mitsuyoshi Takahara MD, PhD ,&nbsp;Takashi Morita MD, PhD ,&nbsp;Shungo Hikosou MD, PhD ,&nbsp;Daisaku Nakatani MD, PhD ,&nbsp;Toshiaki Mano MD, PhD ,&nbsp;Takahisa Yamada MD, PhD ,&nbsp;Takahumi Ueno MD, PhD ,&nbsp;Yasushi Sakata MD, PhD","doi":"10.1016/j.amjcard.2025.01.009","DOIUrl":"10.1016/j.amjcard.2025.01.009","url":null,"abstract":"<div><div>A dual-therapy sirolimus-eluting and CD34+ antibody–coated Combo Stent (DTS) has been developed to enhance endothelization and capture endothelial progenitor cells; however, vessel responses following DTS implantation remain unclear. Therefore, we evaluated early- and mid-term intravascular characteristics of DTS using intravascular imaging modalities. This multicenter, prospective, observational study enrolled 88 patients (95 lesions) who underwent DTS (43 patients, 48 lesions) or sirolimus-eluting Orsiro stent (SES, 45 patients, 47 lesions) implantation. Serial optical coherence tomography (OCT) and coronary angioscopy (CAS) findings were compared between the groups at 1 and 12 months.The OCT findings were similar between the DTS and SES groups at 1 month, including the covered strut rate (84.21 ± 9.50% versus 80.56 ± 17.68%, p = 0.27). CAS findings were also comparable despite a more severe yellow coloration observed in the DTS group (p = 0.006). At 12 months, OCT findings revealed that the covered and adequate strut coverage (≥40 μm) rates were significantly higher (99.27 ± 0.95% versus 95.46 ± 5.56%, p &lt;0.001 and 88.90 ± 10.15% versus 72.96 ± 16.48%, p &lt;0.001) and neointimal thickness was significantly thicker (152.16 ± 70.31 versus 84.39 ± 29.80 μm, p &lt;0.001) in DTS than in SES. The malapposed strut rate was significantly higher in SES than in DTS (0.04 ± 0.18% versus 0.82 ± 1.87%, p = 0.018). CAS revealed that the yellow coloration (p = 0.049) and subclinical intrastent thrombus (p = 0.019) were less severe in DTS than in SES at 12 months. In conclusion, DTS provided better advantages regarding strut coverage and plaque stabilization compared to SES. However, given the observational nature of this study, further randomized controlled trials are needed to confirm these findings.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"241 ","pages":"Pages 26-36"},"PeriodicalIF":2.3,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143035813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial Strain: A Physiologic Concept Overstretched Into Clinical Relevance?","authors":"Catalin Loghin MD","doi":"10.1016/j.amjcard.2025.01.023","DOIUrl":"10.1016/j.amjcard.2025.01.023","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"242 ","pages":"Pages 93-94"},"PeriodicalIF":2.3,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143035911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet Therapy in PCI Patients: A Systematic Review and Meta-Analysis","authors":"Giulia Alagna,&nbsp;Giancarlo Trimarchi,&nbsp;Alessia Cascone,&nbsp;Alessio Villari,&nbsp;Giulia Cavolina,&nbsp;Francesca Campanella,&nbsp;Antonino Micari,&nbsp;Giovanni Taverna,&nbsp;Giuseppe Andò","doi":"10.1016/j.amjcard.2025.01.014","DOIUrl":"10.1016/j.amjcard.2025.01.014","url":null,"abstract":"<div><div>Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the standard treatment for patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). However, the optimal duration of DAPT remains debated due to the need to balance ischemic event reduction with bleeding risks. This study evaluates the efficacy and safety of ticagrelor monotherapy after short-duration DAPT (1 to 3 months) compared to extended DAPT, focusing on major bleeding and cardiovascular outcomes. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Randomized controlled trials (RCTs) comparing ticagrelor monotherapy after short-duration DAPT to extended DAPT were identified from PubMed, Embase, and the Cochrane Library. Data on major bleeding, major adverse cardiovascular and cerebrovascular events (MACCE), myocardial infarction, stroke, stent thrombosis, and mortality were analyzed, and risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model. Five RCTs involving 32,393 patients were included. Ticagrelor monotherapy significantly reduced MACCE (RR: 0.88; 95% CI: 0.77 to 0.99; p = 0.04) and major bleeding (RR: 0.53; 95% CI: 0.37 to 0.77; p = 0.0008) compared to extended DAPT. It also significantly reduced all-cause mortality (RR: 0.82; 95% CI: 0.67 to 0.99; p = 0.04) and cardiovascular death (RR: 0.68; 95% CI: 0.49 to 0.94; p = 0.02). The incidence of myocardial infarction, stent thrombosis, and stroke were similar between the groups. Net adverse clinical events (NACE) were 27% lower with ticagrelor monotherapy (RR: 0.73; 95% CI: 0.63 to 0.85; p &lt;0.0001). In conclusion, ticagrelor monotherapy after short-duration DAPT reduces major bleeding complications without compromising cardiovascular protection. This approach offers a promising strategy to optimize outcomes for PCI patients, particularly those at high bleeding risk. Further studies are needed to refine the optimal DAPT duration in various patient populations, especially those with higher ischemic risk.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"241 ","pages":"Pages 69-74"},"PeriodicalIF":2.3,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143035815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral Venous Pressure-Guided Decongestive Therapy in Heart Failure 2 (PERIPHERAL-HF2)","authors":"Kartal Emre Aslanger MD ,&nbsp;Funda Özlem Pamuk MD ,&nbsp;Yaser İslamoğlu MD ,&nbsp;Yelda Saltan Özateş MD ,&nbsp;Doğan İliş MD ,&nbsp;Esra Dönmez MD ,&nbsp;Sevgi Özcan MD ,&nbsp;Ezgi Çamlı Babayiğit MD ,&nbsp;Mevlüt Demir MD ,&nbsp;Taner Şen MD ,&nbsp;Özlem Yıldırımtürk MD ,&nbsp;on behalf of PERIPHERAL-HF2 Investigators","doi":"10.1016/j.amjcard.2025.01.018","DOIUrl":"10.1016/j.amjcard.2025.01.018","url":null,"abstract":"<div><div>Congestive symptoms are the primary cause of hospitalizations in heart failure (HF), and diuretics remain the cornerstone of their management. However, clinical practice varies widely due to a lack of a reliable measure of congestion guiding diuretic use. Consequently, many HF patients are discharged prematurely without adequate decongestion, leading to increased readmissions and mortality. Peripheral venous pressure (PVP) has emerged as a promising noninvasive measure of vascular congestion. This study will enroll 650 patients aged 18-99 years admitted with de novo or acutely decompensated chronic HF. In the standard care arm, diuretic dosing and discharge decisions will be at the physician's discretion. In the PVP-guided arm, the goal is to maintain a PVP of &lt;9 mmHg, with diuretic dosing adjusted based on daily PVP changes and urine output. The primary outcome is a composite of all-cause mortality, hospitalizations, and emergency department visits, with secondary outcomes including cardiovascular mortality and HF-related readmissions. We hypothesize that PVP-guided diuretic therapy will provide more precise and effective decongestion than standard care, reducing rehospitalizations and mortality. In conclusion, this study will offer valuable insights into the relationship between diuretic therapy, vascular congestion, and cardiac and renal outcomes.</div><div>Trial registration: ClinicalTrials.gov Identifier: NCT06495892</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"241 ","pages":"Pages 37-42"},"PeriodicalIF":2.3,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143035922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Outcomes of Left Main and Nonleft Main Percutaneous Coronary Intervention from the Excellence in Coronary Artery Disease (XLCAD) Registry","authors":"Robert C. Stoler MD ,&nbsp;Minseob Jeong MD ,&nbsp;Talha Akram BS ,&nbsp;Alec Monhollen BS ,&nbsp;David Fernandez Vazquez MD ,&nbsp;Mufaddal Mamawala MBBS, MPH ,&nbsp;Trenton A. Witt BA ,&nbsp;Blake Bruneman BS ,&nbsp;Sarah Weideman BS ,&nbsp;Kennedy S. Adelman BS ,&nbsp;Shalini Sharma BS ,&nbsp;Yumna Furqan BS ,&nbsp;Zachary P. Rosol MD ,&nbsp;Ronak Rengarajan MD ,&nbsp;Jeffrey M. Schussler MD ,&nbsp;Ravi C. Vallabhan MD ,&nbsp;Yashasvi Chugh MD ,&nbsp;Dong-Hi Anthony Yoon MD ,&nbsp;Georges A. Feghali MD ,&nbsp;Carlos E. Velasco MD ,&nbsp;Subhash Banerjee MD","doi":"10.1016/j.amjcard.2025.01.008","DOIUrl":"10.1016/j.amjcard.2025.01.008","url":null,"abstract":"<div><h3>Background</h3><div>There are limited comparative data on real-world outcomes of patients undergoing percutaneous coronary intervention (PCI) of the left main (LM) and non-LM coronary arteries.</div></div><div><h3>Methods</h3><div>Total 873 consecutive patients undergoing LM PCI (n = 256) and non-LM PCI (n = 617) were enrolled between September 2019-March 2023 in the Excellence in Coronary Artery Disease (XLCAD) Registry. Primary outcome was 1-year incidence of major adverse cardiovascular events (MACE), a composite of all-cause death, nonfatal myocardial infarction, clinically driven repeat revascularization and ischemic stroke. The secondary outcome was periprocedural (≤30 days) events.</div></div><div><h3>Results</h3><div>Study cohort included 68% men, mean age 71.9 ± 10.3 in LM and 67.2 ± 11.1 years in non-LM PCI groups (p &lt;0.001). LM PCI patients had significantly greater co-morbidities (diabetes mellitus, hyperlipidemia, prior stroke, prior myocardial infarction, prior coronary revascularization, peripheral artery disease, chronic lung and kidney disease and heart failure) compared with non-LM. Acute coronary syndrome indication was the most prevalent (69%). Mechanical circulatory support was employed in 3.1% LM vs 1% non-LM PCI patients (p = 0.026). Mean number of lesions treated were 2.2 ± 1.0 in LM and 1.4 ± 0.6 in non-LM PCI groups (p &lt;0.001). Multivessel PCI was performed in 68.8% LM and 21% non-LM PCI patients (p &lt;0.001). Overall, drug-eluting stent use (96.7%), bifurcation PCI (24.7%) and atherectomy (2.4%) were similar across groups. Technical and procedural success rates were high across groups, however significantly higher in non-LM group. Periprocedural (≤30 days postprocedure) events included mortality in 3.5% LM and 1.5% non-LM PCI (p = 0.334) and MACE 4.7% LM vs 2.4% non-LM PCI (p = 0.080) groups. One-year MACE was significantly higher in LM versus non-LM PCI (12.9% vs 8.4%, respectively; p = 0.043), driven mainly by higher repeat percutaneous revascularization in LM group (12.1% vs 6.2%; p = 0.003). Mortality at 1-year in LM vs non-LM PCI were 10.2% vs 5.8% (p = 0.074).</div></div><div><h3>Conclusion</h3><div>In a real-world experience, LM PCI is performed in patients with significantly greater comorbidities compared with non-LM PCI, with high procedural success. Thirty-day mortality and 1-year MACE are significantly higher in LM group.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"241 ","pages":"Pages 17-25"},"PeriodicalIF":2.3,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid Management in United States Commercial and Medicare Enrollees With Atherosclerotic Cardiovascular Disease: Treatment Patterns and Low-Density Lipoprotein Cholesterol Control","authors":"Ann Marie Navar MD, PhD ,&nbsp;Batul Electricwala PhD ,&nbsp;Jasjit K. Multani MPH ,&nbsp;Zifan Zhou MS ,&nbsp;Chi-Chang Chen PhD, MsPharm ,&nbsp;Barnabie C. Agatep MPH ,&nbsp;Allison A. Petrilla MPH ,&nbsp;Taylor T. Schwartz MPH ,&nbsp;Laetitia N'dri PharmD ,&nbsp;Joaquim Cristino MSc ,&nbsp;Fatima Rodriguez MD, MPH","doi":"10.1016/j.amjcard.2024.12.029","DOIUrl":"10.1016/j.amjcard.2024.12.029","url":null,"abstract":"<div><div>Lipid-lowering therapy (LLT) is the cornerstone for secondary prevention of atherosclerotic cardiovascular disease (ASCVD); however, many patients exhibit low adherence to therapy and fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. This retrospective cohort study used 2 nationally representative closed administrative claims databases (PharMetrics Plus and Medicare Fee-for-Service Research Identifiable Files) to identify commercial and Medicare enrollees with ASCVD between 2014 and 2019. Patients were stratified by exposure to statin therapy, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i mAb) regimens. Outcomes included LLT adherence (proportion of days covered ≥0.8), persistence, and discontinuation at 12 months. For patients with LDL-C test results, the percentage of patients achieving LDL-C &lt;70 mg/100 ml during follow-up was evaluated. We identified 4.6 million patients with ASCVD (commercial: 945,704; Medicare: 3,659,011), with the majority having ischemic or coronary heart disease. Of these, 66.4% commercial and 71.4% Medicare patients were on at least 1 LLT, including 69.8% commercial and 71.4% Medicare patients on statin therapy, 2.7% commercial and 1.7% Medicare patients on ezetimibe, and 0.2% commercial and 0.04% Medicare patients on a PCSK9i mAb. By 12 months, medication discontinuation was as follows: 30.4% commercial and 34.1% Medicare for statin therapy, 35.5% commercial and 46.1% Medicare for ezetimibe, and 41.5% commercial and 55.8% Medicare for PCSK9i mAb. Approximately half of the treated patients remained adherent after 12 months. Of patients with LDL-C data available (n = 381,160), &lt;20% achieved an LDL-C &lt;70 mg/100 ml. In conclusion, medication discontinuation and low adherence to statin, ezetimibe, and PCSK9i mAb therapies were observed in both populations. Increased efforts are needed to ensure persistence and adherence to LLT in patients with ASCVD to attain LDL-C targets.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"242 ","pages":"Pages 1-9"},"PeriodicalIF":2.3,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can ChatGPT 4.0 Diagnose Acute Aortic Dissection? Integrating Artificial Intelligence into Medical Diagnostics","authors":"Aman Goyal MBBS ,&nbsp;Muhammad Daoud Tariq MBBS ,&nbsp;Areeba Ahsan MBBS ,&nbsp;Andrei Brateanu MD","doi":"10.1016/j.amjcard.2025.01.010","DOIUrl":"10.1016/j.amjcard.2025.01.010","url":null,"abstract":"<div><div>Acute aortic dissection (AD) is a critical condition characterized by high mortality and frequent misdiagnoses, primarily due to symptom overlap with other medical pathologies. This study explores the diagnostic utility of ChatGPT 4.0, an artificial intelligence model developed by OpenAI, in identifying acute AD from patients’ presentations and general physical examination findings documented in published case reports. A systematic search was conducted on the PubMed database using the search term “acute aortic dissection,” applying filters for articles published within the past year and categorized as case reports. The primary symptoms and physical examination details from each case were inputted into ChatGPT 4.0, which was prompted to generate three differential diagnoses and one main provisional diagnosis based on the case presentation. The search yielded a total of 163 results, from which 10 case reports were randomly selected. The patient demographics across all 10 case reports demonstrated an age range of 29 to 82 years, with equal gender distribution (5 males, 5 females) and hypertension as the most prevalent baseline comorbidity. ChatGPT 4.0 accurately identified acute AD as one of the top three differential diagnoses in all selected cases and identified acute AD as the provisional diagnosis in five of the 10 cases. In conclusion, while ChatGPT 4.0 demonstrates potential in suggesting acute AD as a differential diagnosis based on clinical data, its role should be considered supportive rather than definitive. Based on our findings, it could serve as an early, cost-effective, and quick screening tool, helping physicians adopt a “think aorta” approach.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"239 ","pages":"Pages 90-92"},"PeriodicalIF":2.3,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Patients With Chest Pain Using the Recalibrated HEART Score and a Single High Sensitive Cardiac Troponin Measurement","authors":"Vernon V.S. Bonarjee MD, PhD","doi":"10.1016/j.amjcard.2024.09.016","DOIUrl":"10.1016/j.amjcard.2024.09.016","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"235 ","pages":"Pages 91-92"},"PeriodicalIF":2.3,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epinephrine for Refractory No-Reflow During Percutaneous Coronary Interventions","authors":"Fernando Alfonso MD ,&nbsp;Josep Gómez-Lara MD ,&nbsp;Fernando Rivero MD","doi":"10.1016/j.amjcard.2024.08.023","DOIUrl":"10.1016/j.amjcard.2024.08.023","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"235 ","pages":"Pages 88-90"},"PeriodicalIF":2.3,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}